<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01370980</url>
  </required_header>
  <id_info>
    <org_study_id>139/10</org_study_id>
    <nct_id>NCT01370980</nct_id>
  </id_info>
  <brief_title>Collaborative Seamless Care in Oncology : Measure and Reinforce Safety and Adherence to Oral Cancer Treatment</brief_title>
  <official_title>Collaborative and Seamless Care in Oncology : a Study in Primary Care to Measure and Reinforce Safety and Adherence to Oral Cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Policlinique Médicale Universitaire</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre Hospitalier Universitaire Vaudois</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Policlinique Médicale Universitaire</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to implement a support interdisciplinary program(oncologists,
      pharmacists, physicians, nurses, leagues against cancer) of medication adherence to oral
      oncology treatments. The aim is to ensure continuity of care between
      professionals,effectiveness of treatment and patient safety.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      80 patients will be included in swiss-romande hospitals and private oncologists and followed
      by thirty study pharmacies. Each refusal and drop-out will be documented. Follow-up duration
      is 48 weeks, with a motivational interviewing at least every three months. Patient adherence
      will be assessed electronically by MEMS (Medication Event Monitoring System).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Medication adherence</measure>
    <time_frame>3 months, 6 months, 9 months, 12 months</time_frame>
    <description>MEMS data, completed by informations given in motivational interviewing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Program implementation</measure>
    <time_frame>1 year</time_frame>
    <description>Evaluating the implementation of the program in pharmacies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oncologists, nurses, pharmacists and patients satisfaction</measure>
    <time_frame>1 year</time_frame>
    <description>By questionnaire and interviews</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Adverse Drug Reaction (ADR) on medication adherence</measure>
    <time_frame>1 year</time_frame>
    <description>By MEMS data and motivational interviewing informations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Adverse Drug Reaction (ADR)</measure>
    <time_frame>3 months, 6 months, 9 months, 12 months</time_frame>
    <description>To evaluate the frequency and severity of ADR and the pharmacist's contribution to their management. Data from motivational interviewing.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Study population</arm_group_label>
    <description>Adults (18 years old or more) with one of the following oral oncology treatments: letrozole, exémestane, imatinib, sunitinib, nilotinib, evérolimus, déférasirox</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with cancer treated by oral medication in swiss-romande hospitals and private
        oncologists, and enrolled in the adherence program in one of the thirty studies pharmacies.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years and older

          -  Treated for a cancer with oral medication (letrozol, exemestan,imatinib, sunitinib,
             nilotinib, everolimus, deferasirox)

          -  French speaking

        Exclusion Criteria:

        - None
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bugnon Olivier, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Policlinique Médicale Universitaire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lüthi François, Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Clinique Bois-Cerf, Lausanne</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Schneider Marie-Paule, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinique Medicale Universitaire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chevaux Bernard, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Troxler Stéphanie, PhD Student</last_name>
    <role>Principal Investigator</role>
    <affiliation>Policlinique Medicale Universitaire</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Leila Achtari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Univeristaire Vaudois</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Policlinique Médicale Universitaire and Centre pluridisciplinaire d'oncologie, CHUV</name>
      <address>
        <city>Lausanne</city>
        <state>Vaud</state>
        <zip>1010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bugnon Olivier</last_name>
      <phone>+41 21 314 48 48</phone>
      <email>Olivier.Bugnon@hospvd.ch</email>
    </contact>
    <contact_backup>
      <last_name>Schneider Marie-Paule</last_name>
      <phone>+41 21 314 48 46</phone>
      <email>Marie-Paule.Schneider@hospvd.ch</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>July 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2011</study_first_submitted>
  <study_first_submitted_qc>June 9, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2011</study_first_posted>
  <last_update_submitted>July 16, 2012</last_update_submitted>
  <last_update_submitted_qc>July 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Policlinique Médicale Universitaire</investigator_affiliation>
    <investigator_full_name>Marie Schneider</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>Medication Adherence</keyword>
  <keyword>Patient Compliance</keyword>
  <keyword>Patient Acceptance of Health Care</keyword>
  <keyword>Administration, Oral</keyword>
  <keyword>Cancer</keyword>
  <keyword>Letrozol</keyword>
  <keyword>Exemestan</keyword>
  <keyword>Imatinib</keyword>
  <keyword>Sunitinib</keyword>
  <keyword>Nilotinib</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Deferasirox</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Deferasirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

